Pharmacokinetics of cefotaxime in newborn infants

Area of Science:

• Pharmacology
• Neonatal Medicine
• Clinical Pharmacy

Background:

• Cefotaxime is a crucial antibiotic for treating serious infections in neonates.
• Understanding cefotaxime pharmacokinetics in newborns is essential for safe and effective therapy.
• Infant pharmacokinetics, especially in neonates, can differ significantly from adults due to physiological immaturity.

Purpose of the Study:

• To determine the pharmacokinetics of cefotaxime in newborn infants aged 1 to 7 days.
• To establish a basis for a cefotaxime dosage schedule tailored to neonatal populations.
• To compare cefotaxime pharmacokinetic parameters between low and average birth weight infants.

Main Methods:

• Intravenous infusion of cefotaxime (50 mg/kg over 10 minutes) administered to newborn infants.
• Serum concentrations of cefotaxime were measured post-infusion.
• Pharmacokinetic parameters including peak serum concentration, elimination half-life, and clearance were calculated.

Main Results:

• Mean peak serum concentrations of 116 and 132 µg/mL were observed in low and average birth weight infants, respectively.
• Mean elimination half-lives were 4.6 hours for low birth weight and 3.4 hours for average birth weight infants.
• Serum clearance rates were 23 mL/min/1.73 m² for low birth weight and 44 mL/min/1.73 m² for average birth weight infants.

Conclusions:

• Significant pharmacokinetic differences exist between low and average birth weight neonates.
• The data support the development of a specific cefotaxime dosage regimen for newborn infants.
• This research provides critical information for optimizing antibiotic therapy in vulnerable neonatal populations.